Advertisement
Advertisement
U.S. markets close in 38 minutes
Advertisement
Advertisement
Advertisement
Advertisement

OncoCyte Corporation (OCX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.3821-0.0059 (-1.52%)
As of 03:01PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close0.3880
Open0.3700
Bid0.3753 x 1000
Ask0.3890 x 2900
Day's Range0.3700 - 0.3890
52 Week Range0.2420 - 1.7500
Volume239,039
Avg. Volume394,698
Market Cap45.334M
Beta (5Y Monthly)1.70
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for OCX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • OncoCyte Corporation
    Daily – Vickers Top Insider Picks for 09/27/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • MarketWatch

    Oncocyte cuts 40% of staff

    Oncocyte Corp. shares rose 5% in premarket trades after the Irvine, Calif., molecular diagnostics company for the detection of cancer, said it would reduce more than 40% of its workforce "to align its team towards key products that address larger markets." As of Dec. 31, 2021, the company employed full-time 110 people, according to Oncocyte's annual report. The positions of Gisela Paulsen, president and chief operating Officer, and Douglas Ross, chief scientific officer, will be eliminated. Onco

  • Simply Wall St.

    The past year for OncoCyte (NASDAQ:OCX) investors has not been profitable

    Even the best investor on earth makes unsuccessful investments. But serious investors should think long and hard about...

  • Simply Wall St.

    How Much Of OncoCyte Corporation (NASDAQ:OCX) Do Insiders Own?

    The big shareholder groups in OncoCyte Corporation ( NASDAQ:OCX ) have power over the company. Institutions often own...

Advertisement
Advertisement